Cantor Fitzgerald Maintains Overweight on Gilead Sciences, Raises Price Target to $175
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice TargetHot
Cantor Fitzgerald analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $155 to $175.
Cantor Fitzgerald analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and raises the price target from $155 to $175.